Tempest Therapeutics, Inc.
About
Issuer
- Entity type
- Corporation
- Jurisdiction
- Delaware
- Sector
- Biotech
- Headquarters
- Brisbane, CA
- Street
- 2000 Sierra Point Parkway
- Zip
- 94005
Offering
- Total offering
- $2M
- Amount sold
- $2M
- First sale
- Mar 20, 2026
- Min investment
- $0
- Securities
- Equity
- Federal exemption
- Rule 506(b)
- Investors so far
- 3
How this filing compares
Ranked #27 of 47 Biotech filings in April 2026 by offering amount.
Median Biotech filing in April 2026: $3M. This offering is 0.7× the median.
Other California filings this week: 3700 Ascent LLC, 3MR JSW Mission Investors, LP, Beach Point SCF IX Loan LP, Beach Point SCF V LP, Belveron Flagship Fund VIII Investor LP
Leadership
Matthew Angel — Executive Officer (also: Director)
Nicholas Maestas — Executive Officer
Michael Raab — Director
Christine Pellizzari — Director
Ronit Simantov — Director
Stephen Brady — Director
Filing details
Tempest Therapeutics, Inc. filed a Form D with the SEC on April 3, 2026.